PRTN3 and rheumatoid arthritis: In summary, by analysing the data derived from clinical trials as well as retrospective studies and reviews, denosumab seems to be the only currently available antiosteoporotic drug that can be useful in reducing not only systemic but also periarticular bone loss, conditions that are both strongly manifest in ACPA-positive RA patients.